nach oben

International Journal of Clinical Oncology

Erschienen in:

01.07.2016 | Original Article

Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation

verfasst von: Dawei Chen, Shuanghai Liu, Sheng Chen, Zhaowen Wang, Zehua Wu, Kai Ma, Junwei Fan, Zhihai Peng

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Application of the Milan criteria is an effective strategy to select patients with hepatocellular carcinoma (HCC) for liver transplantation, but HCC recurrence is still a major concern. The aim of this study was to determine whether interleukin 6 (IL6) polymorphisms and clinical variables are potential predictors for HCC recurrence and prognosis after transplantation.

Methods

A total of 110 consecutive patients with HCC undergoing liver transplantation were enrolled in the study. Six tag single nucleotide polymorphisms in IL6 were genotyped in both the donors and recipients. Demographic characteristics, HCC features, and IL6 polymorphisms were assessed against HCC recurrence.

Results

Pretransplant hepatitis B virus DNA (P = 0.014), pretransplant serum alpha-fetoprotein (P = 0.035), number of nodules (P = 0.011), diameter of main nodule (P = 0.001), macrovascular invasion (P = 0.001), microvascular invasion (P = 0.001), HCC exceeding the Milan criteria (P < 0.001), and donor rs2069852 AA genotype (P = 0.010) were associated with HCC recurrence. Recurrence-free survival rate and overall survival rate were significantly lower (P = 0.011 and P = 0.026, respectively) in patients whose donor had the rs2069852 AA genotype than in those whose donor had the AG and GG genotypes. Independent risk factors for recurrence-free survival and overall survival were microvascular invasion (P = 0.003; P = 0.002), HCC exceeding the Milan criteria (P < 0.001; P = 0.001), and donor rs2069852 AA genotype (P = 0.002; P = 0.010).

Conclusions

Our data suggest that donor IL6 rs2069852 polymorphisms may be a potential genetic marker for HCC recurrence after liver transplantation in the Han Chinese population.

Lafaro KJ, Demirjian AN, Pawlik TM (2015) Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 24:1–17CrossRefPubMed

Zimmerman MA, Ghobrial RM, Tong MJ et al (2008) Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 143:182–188CrossRefPubMed

Fong ZV, Tanabe KK (2014) The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 120:2824–2838CrossRefPubMed

Bruix J, Gores GJ, Mazzaferro V (2014) Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63:844–855CrossRefPubMedPubMedCentral

Lai Q, Avolio AW, Lerut J et al (2012) Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in East and West. J Hepatol 57:974–979CrossRefPubMed

Rodriguez-Peralvarez M, Tsochatzis E, Naveas MC et al (2013) Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 59:1193–1199CrossRefPubMed

Welker MW, Bechstein WO, Zeuzem S et al (2013) Recurrent hepatocellular carcinoma after liver transplantation—an emerging clinical challenge. Transpl Int 26:109–118CrossRefPubMed

Zheng Z, Gao S, Yang Z et al (2014) Single nucleotide polymorphisms in the metastasis-associated in colon cancer-1 gene predict the recurrence of hepatocellular carcinoma after transplantation. Int J Med Sci 11:142–150CrossRefPubMedPubMedCentral

Dickmann LJ, Patel SK, Rock DA et al (2011) Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 39:1415–1422CrossRefPubMed

10.

Yao J, Feng XW, Yu XB et al (2013) Recipient IL-6-572C/G genotype is associated with reduced incidence of acute rejection following liver transplantation. J Int Med Res 41:356–364CrossRefPubMed

11.

Taub R (2004) Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 5:836–847CrossRefPubMed

12.

Ohishi W, Cologne JB, Fujiwara S et al (2014) Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study. Int J Cancer 134:154–163CrossRefPubMed

13.

Liu Y, Gao SJ, Du BX et al (2014) Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis. Tumour Biol 35:3551–3561CrossRefPubMed

14.

Falleti E, Fabris C, Toniutto P et al (2009) Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology 77:304–313CrossRefPubMed

15.

Fan J, Yang GS, Fu ZR et al (2009) Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 135:1403–1412CrossRefPubMed

16.

Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699CrossRefPubMed

17.

Lai Q, Lerut JP (2014) Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant 19:229–234CrossRefPubMed

18.

Takada Y, Tohyama T, Watanabe J (2015) Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. J Hepato Biliary Pancreat Sci 22:279–286CrossRef

19.

Yao FY, Ferrell L, Bass NM et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394–1403CrossRefPubMed

20.

DuBay D, Sandroussi C, Sandhu L et al (2011) Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 253:166–172CrossRefPubMed

21.

Clavien PA, Lesurtel M, Bossuyt PM et al (2012) Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13:e11–e22CrossRefPubMed

22.

Li MR, Chen GH, Cai CJ et al (2011) High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence. Digestion 84:134–141CrossRefPubMed

23.

Han SH, Reddy KR, Keeffe EB et al (2011) Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant 25:E152–E162CrossRefPubMed

24.

Fitzmorris P, Shoreibah M, Anand BS et al (2015) Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 141:861–876CrossRefPubMed

25.

Duvoux C, Roudot-Thoraval F, Decaens T et al (2012) Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 143:986–994 (e983; quiz e914–985)CrossRefPubMed

26.

Iguchi T, Shirabe K, Aishima S et al (2015) New pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after living-donor liver transplantation. Transplantation 99:1236–1242CrossRefPubMed

27.

Rodriguez-Peralvarez M, Luong TV, Andreana L et al (2013) A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol 20:325–339CrossRefPubMed

28.

Suo GJ, Zhao ZX (2013) Association of the interleukin-28B gene polymorphism with development of hepatitis virus-related hepatocellular carcinoma and liver cirrhosis: a meta-analysis. Genet Mol Res 12:3708–3717CrossRefPubMed

29.

Wei YG, Liu F, Li B et al (2011) Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol 17:3941–3947CrossRefPubMedPubMedCentral

30.

Wei Y, Liu F, Li B et al (2011) Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci 56:2227–2236CrossRefPubMed

31.

Li S, Deng Y, Chen ZP et al (2011) Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population. Infect Genet Evol 11:2083–2088CrossRefPubMed

32.

Taki-Eldin A, Zhou L, Xie HY et al (2012) Liver regeneration after liver transplantation. Eur Surg Res 48:139–153CrossRefPubMed

33.

Johnson C, Han Y, Hughart N et al (2012) Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 1:58–70PubMedPubMedCentral

34.

Naugler WE, Sakurai T, Kim S et al (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121–124CrossRefPubMed

35.

Karimi MH, Daneshmandi S, Pourfathollah AA et al (2011) Association of IL-6 promoter and IFN-gamma gene polymorphisms with acute rejection of liver transplantation. Mol Biol Rep 38:4437–4443CrossRefPubMed

36.

Zhang G, Zhou B, Wang W et al (2012) A functional single-nucleotide polymorphism in the promoter of the gene encoding interleukin 6 is associated with susceptibility to tuberculosis. J Infect Dis 205:1697–1704CrossRefPubMedPubMedCentral

37.

Komatsu Y, Tai H, Galicia JC et al (2005) Interleukin-6 (IL-6)–373 A9T11 allele is associated with reduced susceptibility to chronic periodontitis in Japanese subjects and decreased serum IL-6 level. Tissue Antigens 65:110–114CrossRefPubMed

38.

Brull DJ, Montgomery HE, Sanders J et al (2001) Interleukin-6 gene −174 g > c and −572 g > c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 21:1458–1463CrossRefPubMed

39.

Wu LM, Zhou L, Xu J et al (2013) Lack of association between genetic polymorphisms in cytokine genes and tumor recurrence in patients with hepatocellular carcinoma undergoing transplantation. Hepatobiliary Pancreat Dis Int 12:54–59CrossRefPubMed

40.

Norris CA, He M, Kang LI et al (2014) Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli. PLoS One 9:e96053CrossRefPubMedPubMedCentral

41.

Zhang Y, Shi ZL, Yang X et al (2014) Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis. World J Gastroenterol 20:142–147CrossRefPubMedPubMedCentral

Titel: Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation
verfasst von: Dawei Chen
Shuanghai Liu
Sheng Chen
Zhaowen Wang
Zehua Wu
Kai Ma
Junwei Fan
Zhihai Peng
Publikationsdatum: 01.07.2016
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 6/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1001-1

Springer Medizin

Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients

Association between nuclear expression of retinoic acid receptor alpha and beta and clinicopathological features and prognosis of advanced non-small cell lung cancer

Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study

Intrathoracic extensive-stage small cell lung cancer: assessment of the benefit of thoracic and brain radiotherapy using the SEER database

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass

The impact of body mass index on oncological outcomes in colorectal cancer patients with curative intent

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie